# Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation

> **NCT03723824** · PHASE4 · TERMINATED · sponsor: **Taichung Veterans General Hospital** · enrollment: 14 (actual)

## Conditions studied

- Chronic Hepatitis c
- Liver Transplant Infection
- Kidney Transplant Infection

## Interventions

- **DRUG:** grazoprevir 100 mg/ elbasvir 50 mg, Zepatier®

## Key facts

- **NCT ID:** NCT03723824
- **Lead sponsor:** Taichung Veterans General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-02-14
- **Primary completion:** 2020-11-30
- **Final completion:** 2021-03-13
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** COV-19 pandemic
- **Last updated:** 2021-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03723824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03723824, "Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03723824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*